Intellia Therapeutics, Inc. (NTLA) stock
NTLANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 3/3025% above fair value
$9.70−0.85 (-8.06%)
Close on Nov 13, 2026Market cap $1.36BP/E –Yield –
Intellia Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Intellia Therapeutics's profit margin for the twelve months ending Sep 30, 2026 was -805.7%. For fiscal 2025 it was -609.9%, against -896.8% the year before. The highest annual figure on record is -192.0% in fiscal 2016.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -609.9% | +286.9 |
| FY2024 | Dec 31, 2024 | -896.8% | +429.7 |
| FY2023 | Dec 31, 2023 | -1326.5% | −416.7 |
| FY2022 | Dec 31, 2022 | -909.8% | −99.3 |
| FY2021 | Dec 31, 2021 | -810.5% | −579.0 |
| FY2020 | Dec 31, 2020 | -231.5% | +868.7 |
| FY2019 | Dec 31, 2019 | -1100.1% | −819.7 |
| FY2018 | Dec 31, 2018 | -280.4% | −21.8 |
| FY2017 | Dec 31, 2017 | -258.6% | −66.7 |
| FY2016 | Dec 31, 2016 | -192.0% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -1779.8% | −1044.6 |
| Q2 FY2026 | Jun 30, 2026 | -1392.3% | −681.5 |
| Q1 FY2026 | Mar 31, 2026 | -639.5% | +48.1 |
| Q4 FY2025 | Dec 31, 2025 | -416.2% | +585.1 |
| Q3 FY2025 | Sep 30, 2025 | -735.2% | +754.3 |
| Q2 FY2025 | Jun 30, 2025 | -710.8% | +1401.8 |
| Q1 FY2025 | Mar 31, 2025 | -687.6% | −316.3 |
| Q4 FY2024 | Dec 31, 2024 | -1001.2% | +18.0 |
| Q3 FY2024 | Sep 30, 2024 | -1489.5% | −579.7 |
| Q2 FY2024 | Jun 30, 2024 | -2112.6% | −1294.5 |
| Q1 FY2024 | Mar 31, 2024 | -371.3% | +464.2 |
| Q3 FY2023 | Sep 30, 2023 | -1019.2% | −165.7 |
| Q2 FY2023 | Jun 30, 2023 | -909.8% | −192.2 |
| Q1 FY2023 | Mar 31, 2023 | -818.1% | +487.2 |
| Q4 FY2022 | Dec 31, 2022 | -835.5% | −203.5 |
| Q3 FY2022 | Sep 30, 2022 | -853.5% | +141.0 |
| Q2 FY2022 | Jun 30, 2022 | -717.6% | +332.9 |
| Q1 FY2022 | Mar 31, 2022 | -1305.3% | −588.4 |
| Q4 FY2021 | Dec 31, 2021 | -632.0% | +7.8 |
| Q3 FY2021 | Sep 30, 2021 | -994.5% | −869.2 |
| Q2 FY2021 | Jun 30, 2021 | -1050.5% | −851.3 |
| Q1 FY2021 | Mar 31, 2021 | -716.9% | −470.7 |
| Q4 FY2020 | Dec 31, 2020 | -639.8% | −381.2 |
| Q3 FY2020 | Sep 30, 2020 | -125.3% | +97.3 |
| Q2 FY2020 | Jun 30, 2020 | -199.2% | +31.8 |
| Q1 FY2020 | Mar 31, 2020 | -246.3% | −36.0 |
| Q4 FY2019 | Dec 31, 2019 | -258.6% | −16.6 |
| Q3 FY2019 | Sep 30, 2019 | -222.6% | +83.8 |
| Q2 FY2019 | Jun 30, 2019 | -231.0% | +58.4 |
| Q1 FY2019 | Mar 31, 2019 | -210.3% | +75.6 |
| Q4 FY2018 | Dec 31, 2018 | -242.0% | +117.4 |
| Q3 FY2018 | Sep 30, 2018 | -306.5% | −96.6 |
| Q2 FY2018 | Jun 30, 2018 | -289.4% | −25.9 |
| Q1 FY2018 | Mar 31, 2018 | -285.9% | −82.7 |
| Q4 FY2017 | Dec 31, 2017 | -359.4% | – |
| Q3 FY2017 | Sep 30, 2017 | -209.9% | – |
| Q2 FY2017 | Jun 30, 2017 | -263.5% | – |
| Q1 FY2017 | Mar 31, 2017 | -203.2% | – |
See a number that looks wrong?